These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 36888587)
1. A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy. Kasparian S; Wei O; Tsai NC; Palmer J; Pal S; Lyou Y; Dorff T Oncologist; 2023 Aug; 28(8):699-705. PubMed ID: 36888587 [TBL] [Abstract][Full Text] [Related]
2. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol. Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039 [TBL] [Abstract][Full Text] [Related]
3. Relugolix: A Review in Advanced Prostate Cancer. Shirley M Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173 [TBL] [Abstract][Full Text] [Related]
4. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183 [TBL] [Abstract][Full Text] [Related]
5. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases. Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728 [TBL] [Abstract][Full Text] [Related]
6. Relugolix in the management of prostate cancer. Sahu KK; Tripathi N; Agarwal N; Swami U Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer. Adekunle OA; Seoane-Vazquez E; Brown LM J Am Pharm Assoc (2003); 2023; 63(3):817-824.e3. PubMed ID: 36653276 [TBL] [Abstract][Full Text] [Related]
8. Adherence to Hormonal Therapies in Prostate Cancer. Hafron J; Sangha P; Kung T; Pruett J Urol Pract; 2023 Nov; 10(6):540-546. PubMed ID: 37647139 [TBL] [Abstract][Full Text] [Related]
9. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058 [TBL] [Abstract][Full Text] [Related]
10. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Saad F; Shore ND Ther Adv Med Oncol; 2021; 13():1758835921998586. PubMed ID: 34408793 [TBL] [Abstract][Full Text] [Related]
12. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659 [TBL] [Abstract][Full Text] [Related]
13. A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer. De La Cerda J; Dunshee C; Gervasi L; Sieber P; Belkoff L; Tutrone R; Lu S; Gatoulis SC; Brown B; Migoya E; Shore N Target Oncol; 2023 May; 18(3):383-390. PubMed ID: 37060432 [TBL] [Abstract][Full Text] [Related]
14. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy. Tatenuma T; Miyamoto H Drug Des Devel Ther; 2023; 17():2325-2333. PubMed ID: 37559910 [TBL] [Abstract][Full Text] [Related]
15. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. Gallagher L; Xiao J; Hsueh J; Shah S; Danner M; Zwart A; Ayoob M; Yung T; Simpson T; Fallick M; Kumar D; Leger P; Dawson NA; Suy S; Collins SP Front Oncol; 2023; 13():1289249. PubMed ID: 37916156 [TBL] [Abstract][Full Text] [Related]
16. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Tombal B; Collins S; Morgans AK; Hunsche E; Brown B; Zhu E; Bossi A; Shore N Eur Urol; 2023 Dec; 84(6):579-587. PubMed ID: 37833178 [TBL] [Abstract][Full Text] [Related]
17. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B; N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183 [TBL] [Abstract][Full Text] [Related]
18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
19. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150 [TBL] [Abstract][Full Text] [Related]
20. Relugolix in Clinical Practice: The Best Route for All? Cordes LM; Karzai F; Figg WD; Madan RA Oncologist; 2023 Aug; 28(8):647-650. PubMed ID: 37162497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]